Biomarkers for cardiac dysfunction (cTnI, B-type natriuretic peptide [BNP], and [pro-BNP]) might be elevated in early stages of CCM and usually reflect the severity of liver disease [62]. Here, NPPB is linked to cerebral cavernous malformation.